Voyageur Pharmaceuticals Ltd.

TSXV:VM Stock Report

Market Cap: CA$18.8m

Voyageur Pharmaceuticals Management

Management criteria checks 2/4

Voyageur Pharmaceuticals' CEO is Brent Willis, appointed in Jul 2019, has a tenure of 5.5 years. total yearly compensation is CA$132.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 4.95% of the company’s shares, worth CA$932.06K. The average tenure of the management team and the board of directors is 4 years and 2.3 years respectively.

Key information

Brent Willis

Chief executive officer

CA$132.0k

Total compensation

CEO salary percentage100.0%
CEO tenure5.5yrs
CEO ownership5.0%
Management average tenure4yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Have Insiders Been Buying Voyageur Pharmaceuticals Ltd. (CVE:VM) Shares?

Dec 18
Have Insiders Been Buying Voyageur Pharmaceuticals Ltd. (CVE:VM) Shares?

CEO Compensation Analysis

How has Brent Willis's remuneration changed compared to Voyageur Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Aug 31 2024n/an/a

-CA$2m

May 31 2024n/an/a

-CA$1m

Feb 29 2024n/an/a

-CA$1m

Nov 30 2023CA$132kCA$132k

-CA$1m

Aug 31 2023n/an/a

-CA$2m

May 31 2023n/an/a

-CA$2m

Feb 28 2023n/an/a

-CA$2m

Nov 30 2022CA$131kCA$131k

-CA$2m

Aug 31 2022n/an/a

-CA$2m

May 31 2022n/an/a

-CA$2m

Feb 28 2022n/an/a

-CA$2m

Nov 30 2021CA$110kCA$110k

-CA$2m

Aug 31 2021n/an/a

-CA$2m

May 31 2021n/an/a

-CA$853k

Feb 28 2021n/an/a

-CA$820k

Nov 30 2020CA$43kCA$43k

-CA$1m

Aug 31 2020n/an/a

-CA$1m

May 31 2020n/an/a

-CA$999k

Feb 29 2020n/an/a

-CA$817k

Nov 30 2019CA$63kCA$63k

-CA$552k

Aug 31 2019n/an/a

-CA$798k

May 31 2019n/an/a

-CA$511k

Feb 28 2019n/an/a

-CA$558k

Nov 30 2018CA$60kCA$60k

-CA$556k

Compensation vs Market: Brent's total compensation ($USD91.24K) is below average for companies of similar size in the Canadian market ($USD163.79K).

Compensation vs Earnings: Brent's compensation has increased whilst the company is unprofitable.

CEO

Brent Willis (53 yo)

5.5yrs

Tenure

CA$132,000

Compensation

Mr. Brent Willis, Bsc. Eng., serves as President of Voyageur Pharmaceuticals Ltd. (formerly known as Voyageur Minerals Ltd.) since July 1, 2019 and serves as its Director since October 30, 2017. Mr. Willis...

Leadership Team

NamePositionTenureCompensationOwnership
Brent Willis
President5.5yrsCA$132.00k4.95%
CA$ 932.1k
Bradley Willis
Founder10.3yrsCA$126.00k4.86%
CA$ 915.1k
Albert Deslauriers
Chief Financial Officer2.5yrsCA$105.60kno data
Iryna Saranchova
Chief Scientific Officerless than a yearno datano data

4.0yrs

Average Tenure

Experienced Management: VM's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brent Willis
President7.3yrsCA$132.00k4.95%
CA$ 932.1k
Bradley Willis
Founder5.3yrsCA$126.00k4.86%
CA$ 915.1k
Agustin Gago
Directorless than a yearCA$6.00kno data
Ralph Hesje
Independent Director3.5yrsCA$40.90kno data
Eric Pommer
Independent Director2.3yrsCA$15.00kno data
Eugene Fritzel
Independent Director2.3yrsCA$13.00kno data
Alec Megibow
Member of Scientific Advisory Boardno datano datano data
Deborah Baumgarten
Member of Scientific Advisory Boardno datano datano data
C. Johnson
Member of Scientific Advisory Boardno datano datano data
Sat Somers
Member of Scientific Advisory Boardno datano datano data
Thomas Lauenstein
Member of Scientific Advisory Boardno datano datano data
Kevin McBeth
Director1.4yrsCA$5.50kno data

2.3yrs

Average Tenure

58.5yo

Average Age

Experienced Board: VM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/19 03:08
End of Day Share Price 2025/01/17 00:00
Earnings2024/08/31
Annual Earnings2023/11/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Voyageur Pharmaceuticals Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel AppiahCapital Network by Proactive Investors